P. Barton

Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis

B. Giroir, S. Carroll, P. Scannon, 1997, The Lancet.

Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study.

S. Lawless, B. Giroir, A. Kouatli, 1996, Chest.

A pilot, randomized, controlled clinical trial of lucinactant, a peptide-containing synthetic surfactant, in infants with acute hypoxemic respiratory failure

A. Randolph, B. Markovitz, I. Cheifetz, 2012, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock.

S. Lawless, B. Giroir, A. Kouatli, 1998, The Journal of pediatrics.

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial

Phil Barton, Brahm Goldstein, Michael Levin, 2000, The Lancet.

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

R. Brilli, T. Yeh, B. Giroir, 2004, Pediatrics.

1130: NAVA LEADS TO GREATER INITIAL EXTUBATION SUCCESS IN POSTOPERATIVE CONGENITAL HEART DISEASE PATIENTS

Nasir Mushtaq, Shawn B Sood, P. Barton, 2018 .